CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Learn which credit cards provide the most cash rewards without any fees. Make your spending work harder for you.
26,808 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Hedge fund veteran Dan Loeb argues tech is the most attractive sector in the current rally, warning against draconian...
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
Tesla accelerates margin gains in Q1 2026 as Rivian pushes its R2 strategy through partnerships and new products, hig...
June brought a sharp pullback for software names, and figma stock lost june as AI disruption fears collided with rota...
Costco posted solid June numbers, with a 10.6% rise in sales and a strong e-commerce lift. Yet the stock declined, si...
A reserves-and-resources update put Coeur Mining back in focus, with millions of ounces of gold on the books and a pr...
Investors are watching alarm.com with a focus on how 2026 earnings will unfold. This guide explains the key drivers, ...
Medicare’s new $2,000 out-of-pocket cap on Part D drugs is delivering real relief for retirees, with insulin costs ca...
Nvidia sits at the crossroads of AI, data centers, and gaming, powering a surge in demand that could push revenue wel...
A tight cluster of globally listed equities with durable moats are leading the AI disruption, supported by Goldman Sa...
As markets bounce between frenzy and caution, investors are weighing two paths: a focused bet on seven mega-cap names...